GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS

CAUTION: Investigational device. Limited by United States law to investigational use.

Apr 12, 2022

First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study

Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population

Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure

Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication

First Patients Enrolled in the Gore RELINE MAX Clinical Study

108 patient trial to add evidence for treatment of in-stent restenosis using the GORE® VIABAHN® Endoprosthesis

Gore Applauds Medicare Announcement to Reclassify Endovascular Abdominal Aneurysm Repairs

Decision comes after two-year effort to improve the alignment of payment with cost of treatment for abdominal aortic aneurysms

Physicians Report Early Successes Across Multiple Applications in First-in-Human Uses of GORE® SYNECOR Preperitoneal Biomaterial Hernia Repair Device

New three-layer hybrid biomaterial, ideal for TAR procedures, offering permanent strength and rapid tissue generation for single-stage repairs

W. L. Gore & Associates Receives Innovative Technology Designation from Vizient, Inc. for GORE® SYNECOR Biomaterial

Designation recognizes products that bring improvements to the healthcare industry

GORE® DrySeal Flex Introducer Sheath Advances Care through Access

New sheath provides exceptional access to challenging anatomies and branch vessels